56776-32-0
中文名稱
鹽酸艾替伏辛
英文名稱
6-chloro-N-ethyl-4-methyl-4-phenyl-4H-3,1-benzoxazin-2-amine monohydrochloride
CAS
56776-32-0
分子式
C17H18Cl2N2O
分子量
337.244
MOL 文件
56776-32-0.mol
更新日期
2026/03/11 11:22:50
56776-32-0 結構式
基本信息
中文別名
鹽酸艾替伏辛鹽酸依替福辛
艾替伏辛鹽酸鹽
英文別名
StresaMHOE-36801 hydrochloride
Etifoxine·hydrochloride
NSC 163501
ANTIBIOTIC AT-125
U 42126
2-EthylaMino-6-chloro-4-Methyl-4-phenyl-4H-3,1-benzoxazine Hydrochloride
6-Chloro-2-(ethylamino)-4-methyl-4-phenyl-4H-3,1-benzoxazine hydrochloride
6-Chloro-N-ethyl-4-Methyl-4-phenyl-4H-3,1-benzoxazin-2-aMine Hydrochloride
6-Chloro-2-N-ethyl-4-methyl-4-phenyl-4H-3,1-benzoxazin-2-aminehydrochloride
6-chloro-N-ethyl-4-methyl-4-phenyl-4H-3,1-benzoxazin-2-amine monohydrochloride
物理化學性質
熔點ND
儲存條件-20°C
溶解度二甲基亞砜：≥5mg/mL
形態(tài)粉末
顏色白色至米色
穩(wěn)定性吸濕性
InChI1S/C17H17ClN2O.ClH/c1-3-19-16-20-15-10-9-13(18)11-14(15)17(2,21-16)12-7-5-4-6-8-12;/h4-11H,3H2,1-2H3,(H,19,20);1H
InChIKeySCBJXEBIMVRTJE-UHFFFAOYSA-N
SMILESCl.CCNC1=Nc2ccc(Cl)cc2C(C)(O1)c3ccccc3
鹽酸艾替伏辛價格(試劑級)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-16579R | 鹽酸艾替伏辛 Etifoxine hydrochloride (Standard) | 56776-32-0 | 5 mg | 876元 |
| 2026/06/05 | HY-16579R | 鹽酸艾替伏辛 Etifoxine hydrochloride (Standard) | 56776-32-0 | 10 mg | 1320元 |
| 2026/06/05 | HY-16579R | 鹽酸艾替伏辛 Etifoxine hydrochloride (Standard) | 56776-32-0 | 25 mg | 2400元 |
常見問題列表
生物活性
Etifoxine hydrochloride是一個非苯二氮卓類的、具有 GABA 能的化合物，是 GABAA 受體亞基 α1β2γ2 和 α1β3γ2 的陽性變構調(diào)節(jié)劑。Etifoxine hydrochloride 在嚙齒類動物中顯示出抗焦慮和抗驚厥活性。體外研究
Etifoxine (EFX), at concentrations ranging from 10 to 300 μM (higher concentrations limited its solubility), produces a dose-dependent increase in the [3H]muscimol binding at equilibrium, to 155±2% of its control value at 300 μM EFX.
體內(nèi)研究
Etifoxine competitively inhibits [
35
S]TBPS binding with micromolar potency in rat brain.
Etifoxine (3.125-50 mg/kg) exhibits more pronounced anxiolytic and anticonvulsant effects in the BALB/cByJ mice compared to the C57BL/6J mice.
| Animal Model: | Six-week old BALB/cByJ and C57BL/6J mice (20-25 g). |
| Dosage: | 3.125-50 mg/kg. |
| Administration: | Intraperitoneal inhection. |
| Result: |
Significantly increased the amount of time spent on the open arms at the 12.5 mg/kg dose when compared to vehicle (p = 0.009) in BALB/cByJ mice but produced no effect in C57B/6J mice.
BALB/cByJ mice compared with C57BL/6J mice exhibited significantly (p < 0.012) lower plasma levels of the compound at 15 and 30 min. |